DiagnosDGNOF +1.00%16 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates DGNOF with a GF Score™ of 16/100 and a GF Value™ of $0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 607 Healthcare Providers & Services companies, Diagnos ranks better than 97.03% on this metric.
The historical rank and industry rank for Diagnos's Days Payable or its related term are showing as below:
DGNOF'
s Days Payable Range Over the Past 10 Years
Min: 47.84 Med: 105.78 Max: 1699.95
Current: 1387
During the past 13 years, Diagnos's highest Days Payable was 1699.95. The lowest was 47.84. And the median was 105.78.
DGNOF's Days Payable is ranked better than 97.03% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 58
vs DGNOF: 1387.00
Diagnos's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Diagnos Days Payable Related Terms
Diagnos Days Payable Historical Data
* Premium members only.
The historical data trend for Diagnos's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Diagnos's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnos Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Diagnos's Days Payable distribution charts can be found below:
* The bar in red indicates where Diagnos's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Diagnos's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnos (DGNOF) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Diagnos and its competitors. Over the past decade, Diagnos' Days Payable has ranged from 47.84 to 1,699.95. According to the industry distribution chart, Diagnos ranks #18 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 3%.
Is Diagnos' Days Payable too high?
Diagnos' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 47.84 to a high of 1,699.95. Based on the distribution chart, Diagnos ranks #18 out of 607 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Diagnos has a GF Score™ of 16/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnos' Days Payable compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Diagnos ranks #18 out of 607 companies for Days Payable. This places Diagnos in the top 3% of its industry — outperforming the majority of peers. The industry median Days Payable is 58.00. Historically, Diagnos' own Days Payable has ranged from 47.84 to 1,699.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.00, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Diagnos and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnos's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnos stock overvalued right now?
Based on GuruFocus' analysis, Diagnos (DGNOF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.18 — trading 253.9% above its estimated fair value. The current Days Payable is 0.00. Diagnos' overall GF Score™ is 16/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Diagnos (DGNOF), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnos (DGNOF) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnos stock appears to be overvalued.
The current stock price of $0.18 is trading 253.9% above its estimated GF Value™ of $0.05.
GuruFocus considers Diagnos to be Significantly Overvalued.
Key valuation signals for DGNOF:
Days Payable: 0.00
GF Value™: $0.05 vs. price of $0.18 (253.9% above fair value)
No single metric tells the full story. See the DGNOF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in a single business segment of Healthcare services. The company has a business presence in Canada, United States of America, Mexico, Chile and others. The company's key revenue is derived from Canada.
16GF Score
Get the complete analysis for DGNOF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DGNOF has been successfully added to your 
